Sheffield,UK, April 2024: SynGenSys, a biotechnology company designing synthetic gene promoter systems to address critical bottlenecks in biopharma manufacturing and enhance cell and gene therapy development, today announced the introduction of CHO.SET®, a library of novel, patentable and tested promoters designed in silico to allow tuneable gene expression, to enhance biomanufacturing processes.
CHO.SET,designed using SynGenSys’ proprietary informatics and design workflow, is alibrary of novel, patentable, fully tested synthetic promoters. The range of off-the-shelf promoters has been designed to deliver exceptional yield improvements for standard, multi-component, and difficult-to express (DTE)proteins. These promoters enhance production efficiency and quality, offering greater yield and stability through the careful combination of proximal promoter elements.Turnaround time is also reduced, with promoter selection to delivery of lead and backup expression vectors completed within 11 weeks.
Professor David James, Co-founderand Chief Technology Officer, SynGenSys, said: “The rate of recombinant gene transcription mediated by commonly used natural promoters (such as viral CMV) limits CHO cell factory productivity. This in turn limits process yield for these high-value products. There is therefore a clear need for a solution, which we feel our new CHO.SET library provides to the biopharma industry.”
